# Orforglipron vs Semaglutide (oral): How They Differ

Source: https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral

Last updated: 2026-10-06

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Comparisons](https://pepvault.app/peptides/compare) Orforglipron vs Semaglutide (oral)

Compared side by side

# Orforglipron vs Semaglutide (oral): how they differ

Reviewed October 2026 [How we check the library](https://pepvault.app/about#library) [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The short answer

Both are daily GLP-1 tablets, made differently: oral semaglutide is the peptide from the weekly shot with an absorption enhancer, so only about 0.4–2% of each tablet is absorbed, while orforglipron is a small molecule (not a peptide) with 77% bioavailability that can be taken with or without food. Both are FDA-approved: oral semaglutide as Rybelsus and Ozempic tablets for type 2 diabetes and Wegovy tablets for weight management, orforglipron as Foundayo for weight management since April 2026. Commonly reported: the easy routine is orforglipron’s main draw, and the strict morning routine the hardest part of oral semaglutide.

## Side by side

| Compared | [Orforglipron](https://pepvault.app/peptides/orforglipron) | [Semaglutide (oral)](https://pepvault.app/peptides/semaglutide-oral) |
| --- | --- | --- |
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Foundayo, LY3502970, Orfo | Rybelsus, Wegovy pill, Ozempic pill, Oral semaglutide |
| What it is | A GLP-1 drug in a once-daily tablet that is not a peptide, so it comes with no fasting or water rules: Lilly's Foundayo, FDA-approved in April 2026 for weight management. | Semaglutide as a daily tablet instead of a weekly shot, FDA-approved as Rybelsus (3, 7 and 14 mg) and Ozempic tablets (1.5, 4 and 9 mg) for type 2 diabetes and as Wegovy tablets (up to 25 mg) for weight management. |
| How it works | Small-molecule (non-peptide) GLP-1 receptor agonist taken as a daily tablet. Because it is a small molecule it is absorbed without the fasting and water rules of oral semaglutide: the label puts its absolute bioavailability at 77% and lets it be taken with or without food. It reduces food intake, likely by lowering appetite, and delays stomach emptying, most after the first dose; in animal studies it reached and activated brain regions that regulate appetite. FDA-approved on April 1, 2026, as Foundayo for chronic weight management, at 0.8 to 17.2 mg once daily. | The same GLP-1 receptor agonist as the weekly injection, made into a daily tablet with an absorption enhancer (SNAC). The Rybelsus and Ozempic tablet label puts absorption at about 0.4–2% of each tablet, which is why tablet doses run in whole milligrams while the weekly shot is a fraction of one. |
| Commonly reported | The easy routine is the main draw, with nausea, constipation or burping mostly in the weeks after each step-up. Its top dose averaged about 11% weight loss at 72 weeks in its main trial. | The strict morning routine is the hardest part, and nausea after each dose step feels much like the injection. Each line has its own dose steps, so log the strength on your pack. |
| Studied range | FDA label: 0.8–17.2 mg, starting dose 0.8 mg. | FDA label: 1.5–25 mg, starting dose 1.5 mg. |
| How often | Daily | Daily |
| Half-life | ~29–49 hours (FDA label; steady levels after about a week of daily tablets) | ~1 week |
| Route | Oral tablet | Oral tablet |
| Typical run | FDA-approved for long-term use alongside diet and activity. ATTAIN-MAINTAIN tested it as the follow-on to weekly injections for keeping weight off. | Not in our library |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping | Nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation |

Typical run: Community practice — opinions vary. Not a clinical recommendation. “Not in our library” means the entry doesn’t hold it.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking orforglipron or Semaglutide (oral)? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

### Orforglipron

- Day 1–30 · 0.8 mg The 0.8 mg start
- Day 31–60 · 2.5 mg 2.5 mg, the second step
- Day 61+ · 5.5 mg 5.5 mg, the first maintenance dose
- Day 91+ · 9 mg 9 mg, an optional step
- Day 121+ · 14.5 mg 14.5 mg, the step before the top
- Day 151+ · 17.2 mg 17.2 mg, the top dose

[Every card for orforglipron, with its sources](https://pepvault.app/peptides/orforglipron#weeks)

### Semaglutide (oral)

Week-by-week cards for Semaglutide (oral) are not in our library.

[Every card for Semaglutide (oral), with its sources](https://pepvault.app/peptides/semaglutide-oral#weeks)

## With this comparison

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Semaglutide (oral)

- [Semaglutide (oral): the full reference](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)

### Studies

- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026)
- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026)
- [Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4](https://pepvault.app/research/semaglutide-oasis-4-2025)
- [All 5 studies](https://pepvault.app/research#semaglutide-oral)

### Compared with

- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Semaglutide vs Semaglutide (oral)](https://pepvault.app/peptides/compare/semaglutide-vs-semaglutide-oral)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Bioavailability](https://pepvault.app/glossary/bioavailability)
- [GLP-1](https://pepvault.app/glossary/glp-1)

## Questions people ask

### How long do orforglipron and Semaglutide (oral) last?

The half-life of orforglipron is ~29–49 hours (FDA label; steady levels after about a week of daily tablets). The half-life of Semaglutide (oral) is ~1 week.

### How often are orforglipron and Semaglutide (oral) taken?

Orforglipron: daily. Route: Oral tablet. Semaglutide (oral): daily. Route: Oral tablet.

### How are orforglipron and Semaglutide (oral) dosed in research?

The FDA label range for orforglipron is 0.8–17.2 mg, with a 0.8 mg starting dose. The FDA label range for Semaglutide (oral) is 1.5–25 mg, with a 1.5 mg starting dose.

### What are the common side effects of orforglipron and Semaglutide (oral)?

For orforglipron, the library lists: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping. For Semaglutide (oral): nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation.

## Each one in full

- [Orforglipron: dosage, half-life & reference guide](https://pepvault.app/peptides/orforglipron)
- [Semaglutide (oral): dosage, half-life & reference guide](https://pepvault.app/peptides/semaglutide-oral)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking orforglipron or Semaglutide (oral)? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking orforglipron or Semaglutide (oral)? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this comparison

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Semaglutide (oral)

- [Semaglutide (oral): the full reference](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)

### Studies

- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026)
- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026)
- [Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4](https://pepvault.app/research/semaglutide-oasis-4-2025)
- [All 5 studies](https://pepvault.app/research#semaglutide-oral)

### Compared with

- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Semaglutide vs Semaglutide (oral)](https://pepvault.app/peptides/compare/semaglutide-vs-semaglutide-oral)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Bioavailability](https://pepvault.app/glossary/bioavailability)
- [GLP-1](https://pepvault.app/glossary/glp-1)

<!--promo-->

PepVault for iPhone

## Taking orforglipron or Semaglutide (oral)? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## More comparisons

- [All peptide comparisons](https://pepvault.app/peptides/compare)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Semaglutide vs Semaglutide (oral)](https://pepvault.app/peptides/compare/semaglutide-vs-semaglutide-oral)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)

## The library

- [The peptide reference library](https://pepvault.app/peptides)
- [Metabolic & GLP-1 peptides](https://pepvault.app/peptides#metabolic)

## Free tools

- [The Dose Guide](https://pepvault.app/lab/dosage)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity are trademarks of their respective owners; PepVault is independent and not affiliated with or endorsed by any manufacturer.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
